China Resources Double-Crane (600062.SH) subsidiary Zhongshuai Pharmaceutical passes drug GMP compliance inspection

Zhitong Finance APP News, China Resources Double-Crane (600062.SH) issued an announcement. Recently, the company's controlling subsidiary Henan Zhongshuai Pharmaceutical Technology Co., Ltd. (referred to as "Zhongshuai Pharmaceutical") received the "Drug GMP Compliance Inspection Notification" issued by the Henan Provincial Medical Products Administration. Production variety: Acetazolamide Sustained-Release Capsules (specification: 0.5g, National Drug Approval Number H20265455); workshop and production line: the solid preparation workshop and capsule production line passed this drug GMP compliance inspection. Acetazolamide Sustained-Release Capsules are the first domestically approved drug for the prevention or improvement of acute mountain sickness, approved for marketing in August 2026, and have not yet formed market sales.